Physician profile
Michael Welsch
NPI 1932175767
$2,136.39
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $219 · 2021: $460 · 2022: $228 · 2023: $875 · 2024: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,082.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,081.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $422.43 | 2020-2024 | Taltz, Olumiant |
| Janssen Biotech, INC. | $310.07 | 2019-2024 | Stelara, Simponi, Simponi Aria |
| Abbvie INC. | $279.87 | 2019-2023 | Rinvoq, Skyrizi, Humira |
| Novartis Pharmaceuticals Corporation | $223.00 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $150.20 | 2020-2024 | Ilumya, Winlevi |
| Pfizer INC. | $144.71 | 2020-2024 | |
| Regeneron Healthcare Solutions, INC. | $107.28 | 2020-2023 | Dupixent |
| Myriad Genetic Laboratories, INC. | $84.42 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $72.00 | 2021-2023 | Jublia, Arazlo, Duobrii |
| Amgen INC. | $65.50 | 2021-2023 | Otezla |
| Leo Pharma INC. | $60.37 | 2021-2024 | Adbry |
| Sanofi-Aventis U.S. LLC | $36.47 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $26.16 | 2024 | Sotyktu |
| Mayne Pharma Commercial LLC | $25.23 | 2019 | |
| Verrica Pharmaceuticals INC. | $20.66 | 2023 | Ycanth |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $19.65 | 2019 | |
| Epi Health, LLC | $18.75 | 2021 | |
| Aclaris Therapeutics, INC. | $16.95 | 2019 | |
| Almirall LLC | $14.43 | 2021 | |
| Leica Microsystems INC. | $13.30 | 2022 | |
| Incyte Corporation | $13.01 | 2023 | Opzelura |
| Vyne Pharmaceuticals INC. | $11.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Welsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.